NeuroSense Therapeutics Ltd.

NasdaqCM:NRSN Stock Report

Market Cap: US$26.6m

NeuroSense Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NRSN?
Owner TypeNumber of SharesOwnership Percentage
Institutions683,7132.96%
General Public10,580,01045.7%
Individual Insiders11,862,30751.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.2%.

Top Shareholders

Top 25 shareholders own 54.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.9%
Yair Goldfinger
4,607,458US$5.3m0%no data
13.3%
Alon Ben-Noon
3,081,600US$3.5m0%no data
9.96%
Abir Raveh
2,303,729US$2.6m0%no data
4.47%
Ariel Gordon
1,034,607US$1.2m0%no data
1.99%
Or Eisenberg
460,008US$529.0k0%no data
1.1%
Citadel Advisors LLC
253,997US$292.1k641%no data
0.53%
Ferenc Tracik
122,951US$141.4k0%no data
0.44%
Morgan Stanley, Investment Banking and Brokerage Investments
102,581US$118.0k0%no data
0.28%
Niva Russek-Blum
65,428US$75.2k0%no data
0.28%
Jane Street Group, LLC, Asset Management Arm
64,636US$74.3k0%no data
0.28%
Hudson River Trading LLC, Asset Management Arm
64,390US$74.0k0%no data
0.28%
Mark Leuchtenberger
64,000US$73.6k0%no data
0.18%
XTX Holdings Limited, Asset Management Arm
41,897US$48.2k-8.91%no data
0.17%
Meitav Investment House Ltd
40,000US$46.0k0%no data
0.16%
Schiketanz Capital Advisors GmbH
37,200US$42.8k0%0.46%
0.12%
Revital Mandil-Levin
28,526US$32.8k0%no data
0.1%
Cary Claiborne
24,000US$27.6k0%no data
0.1%
Christine Pellizzari
24,000US$27.6k0%no data
0.1%
Caren Deardorf
24,000US$27.6k0%no data
0.095%
Hagit Binder
22,000US$25.3k0%no data
0.086%
Stratos Wealth Partners, Ltd
20,000US$23.0k0%no data
0.07%
Commonwealth Equity Services, LLC
16,250US$18.7k28.7%no data
0.069%
Geode Capital Management, LLC
15,870US$18.2k32.7%no data
0.065%
Two Sigma Securities, LLC, Asset Management Arm
15,017US$17.3k0%no data
0.046%
Warberg Asset Management LLC
10,700US$12.3k0%0.05%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 10:23
End of Day Share Price 2025/02/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeuroSense Therapeutics Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Nazibur RahmanMaxim Group